Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Raloxifene (Evista) vs Vitamin B12: Vitamin B12 has the stronger overall evidence (7.5 vs 5.3/10); they're alternatives for bone health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Vitamin B12 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Likely helps
5 of 6 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Raloxifene (Evista) and Vitamin B12 have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the cited MORE and RUTH trials used 60 mg a day, and MORE also tested 120 mg a day: both doses reduced vertebral fracture risk, and the abstract does not compare side effects between them). For off-label male gynecomastia no cited study gives a dose, none covers men or children, and there is no FDA-approved male dose and the male evidence is thin and retrospective.
Any time of day
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
500-1000mcg daily for maintenance; higher for deficiency
Morning (may be energizing), With or without food
Methylcobalamin (sublingual)
Months to years
Years
Throughout use
Throughout use
2-4 weeks
4-8 weeks
Weeks to months
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
Efficacy of different routes of vitamin B12 supplementation for the treatment of patients with vitamin B12 deficiency: A systematic review and network meta-analysis
Irish journal of medical science (2024) · Meta analysis · n=4275
Regarding the hemoglobin level, the pooled effect sizes showed no difference between all routes of administration that could reach statistical significance.
Dosage exploration of combined B-vitamin supplementation in stroke prevention: a meta-analysis and systematic review
The American journal of clinical nutrition (2024) · Meta analysis · n=76664
In areas without and with partial folic acid fortification, combined B-vitamin supplementation significantly reduced the risk of stroke by 34% [RR: 0.66; 95% confidence interval (CI): 0.50, 0.86] and 11% (RR: 0.89; 95% CI: 0.79, 1.00), respectively.
Vitamin Status in Patients with Phenylketonuria: A Systematic Review and Meta-Analysis
International journal of molecular sciences (2024) · Meta analysis · n=3157
24 studies compared 770 people with early-treated PKU and 2387 healthy controls.
Vitamin B12 has a higher evidence score (7.5/10 vs 5.3/10) and wins in 2 of 3 categories.
For bone health, Raloxifene (Evista) has a higher relevance score (76 vs 75).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Tired? Why most "energy" pills only work if they fix a deficit — and how to find yours first.
What’s safe while nursing, the truth about milk-supply herbs, and what to avoid (it passes into milk).
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.